Document Classification

Section Type: METHODS

Text: Nine hundred and ninety-three HIV-infected male or female quality of life substudy patients aged 18 years or older, with CD4 cell counts between 50 and 350 cells/mm3 nave to antiretroviral therapy or with less than 16 weeks of zidovudine therapy, were randomly assigned to one of three daily regimens : zalcitabine 0. 75 mg and zidovudine 200 mg every 8 h (ddC/ZDV) ; saquinavir 600 mg and zidovudine 200 mg every 8 h (SQV/ZDV) ; or saquinavir 600 mg, zalcitabine 0. 75 mg and zidovudine 200 mg every 8 h (SQV/ddC/ZDV).